Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the cloudy skies looming over the Pharmalot campus. After all, the birds are still chirping and a crisp breeze is wafting by. Moreover, this marks the middle of the week, which means we have managed to survive this far. And this calls for celebration, yes? So please join us as we hoist another cup of delicious stimulation. Our choice today is bourbon pecan. Meanwhile, here are a few items of interest. Have a grand day and drop us a line if you hear something saucy…
Aspen Pharmacare (APHNY) reached an agreement to package, sell, and distribute the Johnson & Johnson (JNJ) Covid-19 vaccine under its own brand in Africa, Reuters reports. J&J had contracted Aspen to package the Covid-19 vaccine drug substance into final doses, a process called fill and finish, and supply it back to J&J. This arrangement, however, did not give Aspen rights over who gets the vaccine and where it goes. In a separate statement, J&J said the agreement means that Aspen can now supply the Covid-19 vaccine under the Aspenovax brand to all 55 African countries and multilateral entities supporting Africa’s vaccination plan.
After months of squabbling over allegedly stolen trade secrets, AbbVie (ABBV) has settled litigation with a small company called Alvotech that sought to sell a biosimilar version of the blockbuster Humira medicine, STAT tells us. The settlement is only the latest such deal in which AbbVie has successfully delayed a would-be rival from marketing its own version of the rheumatoid arthritis treatment, which generated $17.3 billion in U.S. sales last year. As in the settlements AbbVie reached with several other drugmakers, Alvotech cannot market its version until next year — in this case, no sooner than July 2023.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
